Immunovant (IMVT) is back in focus after Week 16 data for its IMVT-1402 rheumatoid arthritis trial showed strong response rates in difficult cases, and its latest earnings report highlighted ongoing losses and funding for continued development.

The latest IMVT-1402 update has shifted attention firmly to Immunovant’s pipeline, with a 1-day share price return of 35.26% helping push the stock to a 1-year total shareholder return of 144.23%, signaling strong positive momentum despite ongoing losses.

If this kind of biotech move interests you, it could be worth scanning for other clinical-stage opportunities through our screener of 30 healthcare AI stocks.

After a 144.23% 1 year total return and a move to a fresh five year high, the core question for you is simple: is Immunovant still trading below its long term potential, or has the market already priced in future growth?

Most Popular Narrative: 13.5% Undervalued

At a last close of $35.56 versus a narrative fair value of $41.13, Immunovant is framed as modestly undervalued, with that view anchored in its FcRn pipeline.

The fully enrolled D2T RA study for IMVT-1402, upsized to 170 patients, reflects strong physician and patient engagement that could support broader adoption in difficult to treat autoimmune populations over time, which would be most visible in revenue growth if late stage data are supportive.

Curious what kind of revenue ramp and profit margin shift would need to sit behind that view, and how rich a future earnings multiple that implies?

Result: Fair Value of $41.13 (UNDERVALUED)

However, the story can shift quickly if IMVT-1402 trial results disappoint or if additional equity funding dilutes existing holders more than you are comfortable with.

Another View: What The P/B Ratio Is Telling You

While the narrative fair value points to upside, the current P/B of 8.5x paints a tougher picture. It is higher than the US Biotechs average of 2.3x but below the peer average of 11.6x, so you are paying a premium to the sector but not to closer comparables.

That premium may make sense if you see IMVT’s pipeline as stronger than the wider group, but it also raises the risk that any setback could hit the share price harder than a lower rated stock. The real question is whether that extra valuation stretch still feels comfortable to you or not.

Next Steps

If the mix of upside and risk in this story feels finely balanced, consider acting quickly and reviewing the data yourself, starting with our breakdown of 5 important warning signs.

Looking for more investment ideas?

If this Immunovant update has sharpened your focus, do not stop here. Broaden your watchlist with a few targeted stock searches built around clear financial traits.

• Target potential mispricings by scanning 51 high quality undervalued stocks that combine quality fundamentals with room for a better market perception.
• Strengthen your income focus by checking out 10 dividend fortresses that pair 5%+ yields with an emphasis on resilience.
• Protect your capital by reviewing 67 resilient stocks with low risk scores designed to keep volatility and financial red flags in check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.